Medical Marijuana Inc (OTCMKTS:MJNA) showing dropped of -0.23% and closed at $0.122, after gaining total volume of 5.80M shares. Its earnings per share (EPS) is $0.01 and its beta value stands at -1.69 points and has total market capitalization of $355.93 million and a total of 3.03 billion outstanding shares.
Medical Marijuana Inc (MJNA) on March 21, 2017 announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (AXIM), a world leader in cannabinoid research and development, has retained the services of Ora, Inc., a global Contract Research Organization (“CRO”), to perform the company’s upcoming product development (based on AXIM’ IP) and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the world’s leading ophthalmology CRO for advancing products from pre-clinical through approval and post-market phases.
Ora will run the clinical programs under the supervision of Prof. Robert Ritch, Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York (NYEE). Prof. Ritch is a world-renowned expert in ophthalmology and glaucoma in particular, and has joined AXIM’s Advisory Board in December 2016.
“It is exciting to see AXIM start on pre-clinical efforts alongside esteemed ophthalmology professionals to develop a cannabinoid based eye drop medication that may assist glaucoma sufferers,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “This partnership between AXIM and Ora is another new exciting milestone for AXIM’s clinical development program, as it continues to move forward finding cannabinoid-based solutions for conditions for which there is no effective treatment.
“Over three million Americans have glaucoma, which is the second leading cause of blindness in the world, according to the World Health Organization,” Dr. Titus continued. “We anticipate this partnership to enhance AXIM’s glaucoma and xerophtalmia (dry eye) products development, ultimately improving the well-being of patients across the globe who suffer with these conditions. At this time, it is anticipated that initial development and early stage trials will be performed in Europe but Ora, Inc. will be pushing to receive DEA approval for U.S. trials once the clinical development leads to human trials.”
Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 15.94% and closed at $1.60, with the total traded volume of 27,130.00 shares. During last trade its minimum price was $1.40 and it gained its highest price of $1.65 and has a total of 40.91 million outstanding shares.
On March 9, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, is pleased to announce it has formulated a new Cannabis CBD-based pre-workout sports supplement with Forzagen. Additionally, the company’s joint venture with Karmavore Superfoods is off to a good start, and their chocolates (infused with ETST CBD) are selling well.
The company recently announced a joint venture with Nutrition Specialties and Forzagen, (Earth Science Tech, Enters Multi-Billion Dollar Sports Supplement Industry via Joint Venture with Nutrition Specialties and Forzagen) where Earth Science Tech and Forzagen will formulate new CBD-based sports products. Earth Science Tech will help develop the market in the United States while Forzagen will develop the market in Mexico and other international accounts. Earth Science Tech, together with Forzagen, have formulated a full-spectrum CBD-based pre-workout supplement called Black Demon 2.0. The supplement was formulated for serious athletes, and is incredibly potent. Forzagen and Earth Science Tech will be splitting both the costs and revenues of Black Demon 2.0, and it is currently in the label design phase. It is expected to be bottled and start selling within Q2 or Q3 of 2017.
“We have seen great success with our non-CBD products in the past, but we are expecting even greater success with Black Demon 2.0,” said Forzagen owner, Jose Bucay, “We’ve already have competitive athletes testing the supplement, and have nothing but positive feedback in regards to Black Demon 2.0. We think we’ve got a true hit in the making.”
MassRoots Inc (OTCMKTS:MSRT) decreased -5.20% closed at $0.844 and traded with total volume of 848,859.00 shares, while the average trading remained 584,421.00 shares. During last trade its minimum price was $0.83 and it gained the highest price of $0.88. Its market capitalization was $71.61 million.
MassRoots Inc (MSRT) on March 20, 2017 announced that the company has registered more than one million users on its platform. Through its mobile application, MassRoots enables consumers to rate products and strains based on their efficacy (i.e., working well for back-pain or epilepsy) and then presents this information in easy-to-use formats for consumers to make educated purchasing decisions at their local dispensary.
“MassRoots registering one million users is a significant milestone made possible by the strong support of our shareholders, tireless work of the MassRoots team, and passion of cannabis consumers worldwide,” stated MassRoots Chairman and CEO, Mr. Isaac Dietrich. “In the coming days, we’ll be releasing a revamped website and updates to our mobile application that will significantly enhance our user experience and can be immediately deployed to our vast user base. With the 4/20 holiday season rapidly approaching, we’re preparing for a surge of web traffic, media coverage and user registrations that MassRoots has historically experienced this time of year. We look forward to continuing to expand our market share of cannabis consumers and dispensaries to further drive shareholder value.”